We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
표시할 이벤트가 없습니다.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 13. | 장 마감 후 (AMC) | — | — | — | — | — | 예정 |
| FY2025 Q3 | 2024. 03. 31. | 시각 미정 | — | $5.43 | — | — | $65.3M | 보고됨 |
| FY2025 Q2 | 2023. 12. 31. | 시각 미정 | — | $-1.6 | — | — | $65.3M |
Rating & price-target changes
표시할 리서치 액션이 없습니다.
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
| FY2025 Q1 | 2023. 09. 30. | 시각 미정 | — | $-1.2 | — | — | $65.3M | 보고됨 |
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 657,615 | $868.05M | 0.00% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 614,442 | $712.75M | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Stored first · Google News · Yahoo Finance (English)
Lite Strategy Inc. (LITS) Slides 2.73% as Selling Pressure Mounts Near Key Support - TICK Divergence - thelegaladvocate.com
Lite Strategy Inc. (LITS) Slides 2.73% as Selling Pressure Mounts Near Key Support - TICK Divergence thelegaladvocate.com
Lite Strategy Inc. (LITS) Q4 2024 Earnings: Significant EPS Miss Amid Strategic Challenges - EPS Consistency Score - thelegaladvocate.com
Lite Strategy Inc. (LITS) Q4 2024 Earnings: Significant EPS Miss Amid Strategic Challenges - EPS Consistency Score thelegaladvocate.com
Lite Strategy Inc. (LITS) Q4 2024 Earnings: Significant EPS Miss Signals Operational Challenges - Guidance Update - thelegaladvocate.com
Lite Strategy Inc. (LITS) Q4 2024 Earnings: Significant EPS Miss Signals Operational Challenges - Guidance Update thelegaladvocate.com
Lite Strategy Inc. (LITS) Q4 2024 Earnings: Significant EPS Miss Signals Operational Challenges - Strong Earnings Momentum - thelegaladvocate.com
Lite Strategy Inc. (LITS) Q4 2024 Earnings: Significant EPS Miss Signals Operational Challenges - Strong Earnings Momentum thelegaladvocate.com
Is Lite Strategy (NASDAQ:LITS) In A Good Position To Invest In Growth?